Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da J. Tate

Towards improved measurement of serum free light chains: clinical and laboratory issues
J. Tate  |  P. Mollee  | 
<p>Serum free light chain (FLC) assays are now well established in the diagnosis and monitoring of plasma cell&nbsp;disorders. Nonetheless, the introduction of FLC measurement into clinical laboratories has not been without difficulty.&nbsp;In this paper we ask several questions about FLC measurements and describe some of the limitations and possible&nbsp;solutions. Main analytical issues include difficulties in defining the measurand and specificity requirements for anti-&nbsp;FLC antibodies, inadequate imprecision and bias and a lack of harmonised results across platforms and between&nbsp;different assays with the need for standardised sample dilution procedures to detect antigen excess, nonlinearity and&nbsp;interferences in FLC assays. Among the clinical issues a consistent approach is required to FLC reporting including&nbsp;standardised units, commenting and interpretation, and assay validation is required in specific disease rather than&nbsp;general patient populations. Collaboration is required between assay developers, laboratory scientists and clinicians&nbsp;to overcome these limitations in the next generation of assays.</p>
Biochimica Clinica ; 37(5) 395-404
Opinioni - Opinions
 
Standardisation of cardiac troponin I measurements - the way forward
Standardisation of cardiac troponin I measurements - the way forward
J. Tate  |  M. Panteghini  | 
<p><strong>Cardiac troponin I (cTnI) assays produce different results.</strong> To achieve closer comparability of cTnI values among assays, the use of a suitable reference material is proposed for use to calibrate commercial assays. To assign true cTnI concentrations to this material, establishment of a reference procedure for cTnI is also required.</p>
Biochimica Clinica ; 35(6) 461-464
OPINIONI - OPINIONI